

Combined cerebrospinal fluid metabolomic and cytokine profiling in tuberculosis meningitis reveals robust and prolonged changes in immunometabolic networks

1 **Jeff Tomalka^{1*}, Ashish Sharma¹, Alison G.C. Smith², Teona Avaliani³, Mariam**
2 **Gujabidze³, Tinatin Bakuradze³, Shorena Sabanadze³, Dean P. Jones⁴, Zaza Avaliani³,**
3 **Maia Kipiani³, Russell R. Kempker⁴, Jeffrey M. Collins^{4*}**

4

5 ¹Department of Pathology, Emory University, Emory University School of Medicine, Atlanta,
6 Georgia, USA

7

8 ²Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA

9

10 ³ National Center for Tuberculosis and Lung Diseases, David Tvildiani Medical University,
11 The University of Georgia, Tbilisi, Georgia

12

13 ⁴ Department of Medicine, Division of Infectious Diseases, Emory University School of
14 Medicine, Atlanta, Georgia, USA

15

16

17 *** Correspondence:**

18

19 Name: Jeffrey Tomalka, PhD; Email: jeffrey.alan.tomalka@emory.edu

20 Jeffrey Collins, MD; Email: jeffrey.michael.collins@emory.edu

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

TB meningitis immunometabolic networks

37 **Abstract**

38 Much of the high mortality in tuberculosis meningitis (TBM) is attributable to excessive
39 inflammation, making it imperative to identify targets for host-directed therapies that reduce
40 pathologic inflammation and mortality. In this study, we investigate how cytokines and
41 metabolites in the cerebral spinal fluid (CSF) associate with TBM at diagnosis and during
42 TBM treatment. At diagnosis, TBM patients demonstrate significant increases versus controls
43 of cytokines and chemokines that promote inflammation and cell migration including IL-17A,
44 IL-2, TNF α , IFN γ , and IL-1 β . Inflammatory immune signaling was strongly correlated with
45 immunomodulatory metabolites including kynurenine, lactic acid, carnitine, tryptophan, and
46 itaconate. Inflammatory immunometabolic networks were only partially reversed with two
47 months of effective TBM treatment and remained significantly different versus control CSF.
48 Together, these data highlight a critical role for host metabolism in regulating the inflammatory
49 response to TBM and indicate the timeline for restoration of immune homeostasis in the CSF
50 is prolonged.

51

52

53

54

55

56

57

58

59

60

61

TB meningitis immunometabolic networks

62 INTRODUCTION

63
64 Tuberculosis meningitis (TBM) is the most devastating manifestation of TB disease with
65 high rates of mortality and neurological morbidity.(1) While the etiology of poor clinical
66 outcomes in persons with TBM is multifactorial, including variable penetration of anti-TB drugs
67 into brain and cerebrospinal fluid (CSF),(2) an aberrant immune response in the central
68 nervous system (CNS) is thought to be a significant contributor to morbidity and mortality.(3)
69 This is supported by early animal models of TBM, which revealed that severe
70 immunopathology resulted from both live and dead bacilli.(4) Further, immune reconstitution
71 in immunosuppressed hosts with TBM, such as those with HIV infection, is a risk factor for
72 poor clinical outcomes.(5, 6) Corticosteroids, a therapy broadly targeting the immune
73 dysregulation in TBM, remain the only adjunctive treatment found to reduce mortality and
74 utilized in TBM management (7); however, they are only beneficial in a subset of patients.(8)
75 A better understanding of the host immune response in TBM is critical to develop a new
76 generation of immunomodulatory therapies that can reduce immunopathology and improve
77 clinical outcomes.

78 As with other forms of meningitis, TBM is characterized by broad upregulation of
79 proinflammatory cytokines in the CNS.(9) Yet the specific immune signaling cascades that
80 lead to poor host outcomes remain poorly understood. While increased CSF concentrations
81 of proinflammatory cytokines IL-1 β , TNF α , IL-6, and IFN γ are associated with greater disease
82 severity at diagnosis, studies to date have yielded conflicting results about their impact on
83 long-term morbidity and mortality.(8, 10, 11) Some of this variability may be due to differences
84 in host genetic (12) and metabolic factors (13, 14), which have generally gone unmeasured
85 in studies of TBM. Indeed, differences in tryptophan and eicosanoid metabolism are the only
86 host response pathways shown to impact TBM mortality.(8, 12-14) However, the relationship

TB meningitis immunometabolic networks

87 between metabolic and cytokine signaling in the CNS of TBM patients and the trajectory of
88 these signaling networks during treatment remain largely unexplored.

89 Recent advances in metabolomics and high-density cytokine profiling now allow for
90 high-resolution immunometabolic profiling of the CSF. Using an integrated approach with
91 these two high-resolution methods, we sought to advance our understanding of the
92 relationship between metabolism and cytokine signaling networks in the CNS of persons with
93 TBM. We first sought to understand what metabolites and cytokines in the CSF are associated
94 with TBM and TBM severity. We further aimed to determine how the host metabolic milieu in
95 the CNS may modulate immune signaling by exploring the relationship between cytokines
96 and metabolites in the CSF. Finally, we wanted to determine the time course for the resolution
97 of these immunometabolic signaling cascades over the course of TBM treatment. Our overall
98 goal was to enhance the understanding of host immunometabolic response networks to
99 *Mycobacterium tuberculosis* (*Mtb*) invasion into the CNS and to elucidate their role in
100 pathologic inflammation.(15)

101 MATERIAL AND METHODS

102 Setting and Participants with TBM

103 Persons with TBM were enrolled from the National Center for Tuberculosis and Lung
104 Diseases (NCTLD) in Tbilisi, Georgia as part of a clinical pharmacology study evaluating the
105 penetration of anti-TB drugs into the CNS.(2) Patients aged ≥ 16 years treated in the NCTLD
106 adult TBM ward from January 2018 to December 2019 were eligible for inclusion. All patients
107 suspected of having TBM underwent a lumbar puncture; acid-fast bacilli (AFB) staining, liquid
108 and solid culture, and Xpert MTB/RIF assay were performed on CSF. CSF samples were
109 taken at the time of TBM diagnosis and over the first 2 months of treatment. Treatment
110 regimens were individualized based on treatment history, comorbidities, and drug
111 susceptibility results when available.(16) All patients also received a 6–8-week course of

TB meningitis immunometabolic networks

112 dexamethasone (400–1200mg). Written informed consent was obtained from all study
113 participants and study was approval was obtained from the institutional review boards of
114 Emory University and the NCTLD.

115 Asymptomatic Control Participants

116 De-identified CSF samples from asymptomatic persons enrolled as part of the Emory
117 Healthy Brain Study were used as a control group for comparison to persons with TBM at
118 diagnosis.(17) All study participants had previously provided written informed consent for use
119 of their CSF samples in medical research.

120 Metabolomics analysis

121 De-identified CSF samples were randomized by a computer-generated list into blocks
122 of 40 samples prior to transfer to the analytical laboratory where personnel were blinded to
123 clinical and demographic data. Thawed CSF (65 μ L) was treated with 130 μ l acetonitrile (2:1,
124 v/v) containing an internal isotopic standard mixture (3.5 μ L/sample), as previously
125 described.(18) Samples were centrifuged and supernatants were analyzed using an Orbitrap
126 Q Exactive Mass Spectrometer (Thermo Scientific, San Jose, CA, USA) with dual HILIC
127 positive and c18 negative liquid chromatography (Higgins Analytical, Targa, Mountain View,
128 CA, USA, 2.1 x 10 cm) with a formic acid/acetonitrile gradient. The high-resolution mass
129 spectrometer was operated over a scan range of 85 to 1275 mass/charge (m/z). (19) Data
130 were extracted and aligned using apLCMS (20) and xMSanalyzer (21) with each feature
131 defined by specific m/z value, retention time, and integrated ion intensity.(19) Three technical
132 replicates were performed for each CSF sample and intensity values were median
133 summarized. Identities of targeted metabolites were confirmed by accurate mass, MS/MS
134 and retention time relative to authentic standards.(22)

TB meningitis immunometabolic networks

135 Cytokine detection

136 The commercially available U-PLEX assay by Meso Scale Discovery (MSD) was used
137 for CSF cytokine detection. This assay allows for the evaluation of multiplexed biomarkers by
138 using custom made U-PLEX sandwich antibodies with a SULFO-TAG conjugated antibody
139 and electrochemiluminescence (ECL) detection. Direct quantitation of cytokines was
140 performed using standard curves generated by 4-fold serial dilutions of standard calibrators
141 provided by MSD. Plates were read on the QuickPlex SQ 120 using Methodical Mind™
142 software and plate data analyzed using Discovery Workbench™ software (MSD).

143 Statistics

144 Statistical comparisons of metabolite intensity values (abundance), metabolite
145 concentrations, and cytokine concentrations were performed in R version 4.2.1. All intensity
146 values and concentrations were \log_2 transformed and compared between groups using linear
147 regression, controlling for age and sex.(23) For untargeted analyses, a false discovery rate
148 (FDR) of $q < 0.10$ was used.(24) Metabolic pathway enrichment analysis was performed using
149 *mummichog*.(25, 26) For correlation analyses, CSF metabolite and cytokine concentrations
150 were normalized using log transformation. Integrative network analyses were performed
151 using xMWAS,(27) which automatically determines the minimum association score threshold
152 required to meet the significance criteria based on the number of samples using Student's t-
153 test. Only associations with an $|\text{association score}| \geq 0.54$ significant at $p < 0.05$ were included
154 in the network analysis.

155 RESULTS

156 Participants

TB meningitis immunometabolic networks

157 We studied CSF samples from 17 participants with suspected TBM presenting to the
158 NCTLD and 20 asymptomatic persons in the U.S. (**Table 1**). Among the 17 patients with
159 suspected TBM, five (29%) were microbiologically confirmed with a median CSF white blood
160 cell (WBC) count of 209 cells/mm³, 94% lymphocytes, a median glucose of 40 mg/dL, and
161 total protein of 99 mg/dL. Five persons with TBM were diagnosed with multi-drug-resistant
162 (MDR)-TBM, two of which were identified through microbiologic testing and three of which
163 were diagnosed clinically based on a poor response to first-line therapy.

164 **TB meningitis dramatically alters the CSF metabolome.**

165 We detected 6,596 metabolic features in positive ionization mode and 9,427 in
166 negative ionization mode. Using an FDR-adjusted p-value of 0.1 and log₂ fold-change
167 threshold of 0.5 (1.414-fold increased or decreased), we found 803 metabolic features were
168 significantly increased in the CSF of TBM patients versus controls (672 in positive ionization
169 mode and 132 in negative mode) while 806 metabolic features were decreased (708 in
170 positive mode and 98 in negative mode; **Figure 1A**). Metabolic pathway analysis revealed
171 vitamin D₃, vitamin B₃ and multiple amino acid pathways were enriched in the CSF of TBM
172 patients while caffeine metabolism and multiple pathways in carbohydrate metabolism were
173 enriched in the CSF of control participants (**Figure 1B**).

174 To enhance our understanding of the CSF metabolic changes associated with TBM,
175 we performed a targeted analysis of individual metabolites with confirmed chemical
176 identities.⁽²²⁾ Similar to the untargeted analysis, we found the CSF of TBM patients was
177 characterized by severe perturbations in energy metabolism and multiple immunomodulatory
178 metabolites including elevated concentrations of kynurenines, carnitines, amino acids, and
179 lactate and decreases in tryptophan, pantothenic acid, and itaconate (**Figure 1C**).
180 Hierarchical clustering analysis of significant metabolites showed almost all TBM cases
181 formed a single cluster aside from a single, unconfirmed TBM case (**Figure 1D**). Together,

TB meningitis immunometabolic networks

182 these findings suggest a re-ordering of energy metabolism in the CNS of TBM patients, with
183 a metabolic milieu characterized by both glycolysis and lactate accumulation as well as fatty
184 acid activation. Further, we found CSF concentrations of immunoregulatory metabolites
185 tryptophan, kynurenine and itaconate, all of which are known to play an important role in
186 modulating the immune response to pulmonary TB (26, 28-30), were markedly different in
187 TBM cases versus controls.

188 Heightened inflammatory cytokines and amino acid metabolism in the CSF identify 189 patients with TB meningitis

190 We performed a principal component analysis (PCA) of all 33 cytokines detected in
191 the CSF. We found clear separation between the two groups, which was more pronounced
192 in those with confirmed TBM (**Figure 2A**). This was further displayed when visualizing
193 cytokine data using a row normalized heatmap, where TBM cases separated from
194 asymptomatic controls (**Figure 2B**). TBM cases were characterized by marked elevations in
195 most cytokines, and particularly pro-inflammatory cytokines such as IL-17A, TNF α , IFN γ , and
196 IL-1 β . Increased expression of effector T cell associated cytokines including IL-2, IFN γ , IL-4,
197 IL-17A and IL-15 (31) was also observed in TBM cases while IL-7, a cytokine associated with
198 homeostasis of naïve and central memory T cells,(32) was decreased.

199 To determine the relationship between the metabolic and immune response in the
200 CSF, we performed a correlation analysis of metabolite and cytokine concentrations across
201 asymptomatic controls and persons with TBM at diagnosis. This revealed three clusters of
202 metabolites and cytokines respectively (**Figure 3A**). Cluster 1 cytokines consisted of a large
203 group of predominantly pro-inflammatory cytokines upregulated in TBM patients (**Figure 3B**).
204 This cluster was significantly and positively correlated with metabolite cluster 3, primarily
205 consisting of lactate, amino acids, carnitines, and kynurenines (**Figure 3C**). Cluster 1

TB meningitis immunometabolic networks

206 cytokines were also significantly and negatively correlated with cluster 1 metabolites, which
207 were significantly decreased in TBM cases (**Figure S1A and S1B**). Cluster 2 metabolites and
208 cluster 3 cytokines did not have strong relationships with other soluble mediators, though
209 metabolite cluster 2 was also significantly increased in TBM (**Figure S1C**). Cytokine cluster
210 2, made up of IL-7 and IL-9, was decreased in TBM cases versus controls (**Figure S2A**) and
211 was weakly correlated with metabolite cluster 1 and weakly inversely correlated with
212 metabolite clusters 2 and 3. While cytokine cluster 3, which consisted of TGF β 2, IFN β ,
213 IFN α 2a, IL-21, and IL-33, did not differ in TBM versus controls (**Figure S2B**), it was
214 significantly increased in patients with Grade 2 TBM versus those with Grade 1 TBM (**Figure**
215 **S2C**), indicating an association with disease severity.

216 To determine the network structure between clinical variables and CSF metabolite and
217 cytokine concentrations in TBM, we used a platform-independent framework for integrative
218 network analysis called xMWAS.(27) Using this approach we found TGF β 3 played a central
219 role in the activity network, with significant associations with multiple metabolites including
220 kynurenines and carnitines (**Figure 3D**). While there was only one participant with TBM that
221 was HIV positive, HIV was significantly associated with type I interferons and IFN γ . Confirmed
222 TBM was associated with IL-2, IFN γ , MIP-1 α , IL-15, and IP-10 while TBM grade was
223 associated with IFN β , IL-18, and IL-27. Tryptophan and epinephrine were associated with
224 increased CSF WBC count.

225

226 **Inflammatory immunometabolic changes in TBM persists for months despite** 227 **appropriate treatment**

228 We next examined the trajectory of CSF metabolite and cytokine concentrations after
229 initiation of TBM treatment. Repeat CSF samples were examined 7, 14, 28 and 56 days after

TB meningitis immunometabolic networks

230 treatment initiation. Of the 17 TBM patients enrolled, 3 patients were eventually deemed “non-
231 responders” due to suspected or proven drug resistance, while 14 patients improved clinically
232 on anti-TB therapy. Treatment responders had significant decreases in cluster 1 cytokines at
233 14, 28, and 56 days after treatment initiation (**Figure 4A**). However, after 56 days of
234 appropriate treatment, CSF concentrations of these cytokines remained significantly higher
235 than in asymptomatic controls. After 7 and 14 days of treatment, the three treatment non-
236 responders had higher concentrations of cluster 1 cytokines versus responders, though the
237 difference was not statistically significant (**Figure 4B**). Cluster 2 cytokines were lower in TBM
238 patients versus controls and did not increase with treatment (**Figure S3A**) while cluster 3
239 cytokines were similar to controls at baseline and throughout treatment (**Figure S3B**).

240 In evaluating the metabolome over the course of TBM treatment, we found cluster 1
241 metabolites did not increase with TBM treatment and remained significantly lower than
242 controls after 56 days (**Figure S4A**). Cluster 1 metabolites were lower in non-responders
243 versus responders after 7 days of treatment, though the difference was not statistically
244 significant (**Figure S4B**). Conversely, cluster 2 metabolites were significantly lower after 28
245 days of treatment (**Figure 4C**) and cluster 3 metabolites were significantly lower after 28 and
246 56 days of treatment (**Figure S4C**). However, both remained significantly elevated after 56
247 days of treatment relative to controls. Network analysis of metabolites and cytokines during
248 TBM treatment revealed that metabolites had the strongest association with CSF WBC count
249 during treatment, including lactate, kynurenine, amino acids, and carnitines (**Figure 4D**).
250 Concentrations of MIP-1 α , IL-18 and TNF α were also significantly associated with CSF WBC
251 count.

252 DISCUSSION

253 In this study, we show that multiple metabolic signaling networks are closely
254 associated with the CNS inflammatory response in patients with TBM and that even after

TB meningitis immunometabolic networks

255 initiating TBM treatment, these immunometabolic changes last for an extended duration. Over
256 the course of treatment, it was metabolites, including kynurenine and multiple carnitines, that
257 were most closely associated with elevated WBCs in the CSF rather than cytokines. These
258 findings indicate that metabolic shifts in the CSF of TBM patients are an integral part of the
259 host inflammatory response. Despite recent advances in the treatment of TB disease,(33-35)
260 morbidity and mortality in persons with TBM remains unacceptably high.(1, 3) There is
261 increasing evidence that a dysregulated immune response in the CNS is a primary driver of
262 poor patient outcomes.(3, 36) Our findings strongly support the hypothesis that chronic
263 inflammation and immune dysfunction in the CNS persist despite effective TB treatment and
264 that this may be the root cause of neurological complications, morbidity, and mortality.
265 Studying the molecular networks that modulate pathologic inflammation in TBM is therefore
266 essential to discover strategies to ameliorate inflammatory immunometabolomic changes in
267 the CNS.

268 The simultaneous measurement of 33 cytokines and chemokines in the CSF is, to our
269 knowledge, the most comprehensive assessment of CSF soluble immune mediators in TBM.
270 Similar to previous studies measuring a smaller number of cytokines, we observed a
271 significant shift in the CSF cytokine profile when we compared individuals with TBM to
272 asymptomatic adults.(8, 9) Among the cytokines that were upregulated in the CSF of TBM
273 patients were key modulators of inflammatory T cell and innate immune responses including
274 IFN γ , TNF α , IL-6, GM-CSF, IL-18, and IL-1 β . We also found that TBM was associated with
275 elevation in multiple anti-inflammatory cytokines including IL-10 and TGF- β 3. This suggests
276 that both inflammatory pathways triggered by infection and their counter-regulatory response
277 networks are increased in TBM. In our integrative analysis of TBM cases at the time of
278 diagnosis, chemokines IP-10 and MIP-1 α as well as cytokines IFN γ , IL-15, and IL-2 were

TB meningitis immunometabolic networks

279 significantly associated with confirmed TBM, indicating these soluble mediators are
280 particularly active in TBM cases with higher bacterial burden. The network analysis revealed
281 the cytokines IFN β , IL-27, and IL-18 were significantly associated with higher TBM grade,
282 suggesting a potential role in mediating immunopathology in severe TBM.

283 We found the concentration of multiple immunomodulatory metabolites in the CNS
284 differentiated persons with TBM from asymptomatic controls. Notably, the metabolites
285 itaconate and tryptophan were two of the few metabolites significantly decreased in the CSF
286 of TBM patients versus controls in the targeted analysis. Itaconate concentrations were
287 significantly and inversely correlated with concentrations of most inflammatory cytokines and
288 chemokines including IL-1 β , IL-18, TNF α , IFN γ , MIP-1 α , and MIP-3 α . Itaconate is derived
289 from TCA cycle intermediate cis-aconitate and has been shown to modulate inflammatory
290 signaling in macrophages through inhibition of succinate dehydrogenase (37), induction of
291 Nrf2 (38), and inhibition of inflammasome activation.(39) We have previously shown that
292 itaconate is decreased in plasma of humans with advanced pulmonary TB disease,(28) and
293 mice lacking the enzyme that forms itaconate experience pathologic pulmonary inflammation
294 and rapid mortality.(30) Itaconate has also been shown to inhibit IL-1 β -mediated inflammation
295 in astrocytes(40) and microglia,(41) the latter of which is a primary source of inflammasomes
296 in the CNS.(42) This suggests low CSF itaconate may play a role in an overexuberant CNS
297 inflammatory response. Similar to a previous TBM metabolomics study, we also found that
298 persons with TBM had decreased CSF concentrations of tryptophan(13) and increased
299 concentrations of its immediate metabolite, kynurenine. Induction of tryptophan catabolism
300 via the enzyme indoleamine-2,3-dioxygenase-1 (IDO1) is a hallmark of TB disease regardless
301 of the affected organ system.(26) Kynurenine and its metabolites are ligands of the aryl
302 hydrocarbon receptor (AHR), which promotes differentiation of regulatory T cells (Tregs) at

TB meningitis immunometabolic networks

303 the expense of Th17 cells.(43-45). This has the effect of limiting T cell effector function and
304 inflammation. This effect is likely protective in TBM, where decreased T cell activation would
305 be expected to reduce immunopathology. Indeed, increased tryptophan catabolism in the
306 CNS of persons with TBM has been associated with increased survival.(13, 14) We observe
307 significantly elevated Th1 (IL-2, IFN γ), Th2 (IL-4) and Th17 (IL-17, IL-6, TNF α) effector
308 cytokines in the CSF of persons with TBM,(31) and these cytokines were correlated with CSF
309 concentrations of kynurenine and kynurenic acid. This indicates tryptophan catabolism
310 represents a counter-regulatory process to limit T-cell-mediated inflammation.(46)

311 We also found metabolic changes in the CSF of TBM patients that were consistent
312 with broad shifts in energy metabolism. Persons with TBM had significant increases in
313 multiple carnitines as well as lactate, suggesting simultaneous activation of beta-oxidation of
314 fatty acids and glycolysis. In the integrative analysis, these metabolic networks were all
315 significantly associated with TGF β signaling. Such metabolic changes may therefore
316 stimulate TGF β secretion or occur as a result of TGF β upregulation. During treatment lactate,
317 kynurenine, and carnitines, along with IL-18, MIP-1 α , and TNF α were significantly associated
318 with CSF WBC count. Elevated expression of chemokines promotes the migration of myeloid
319 and lymphoid cells into the CSF where they are then activated for inflammatory cellular
320 responses by cytokines including IL-1 β , IL-6, IL-18, TNF α , and IFN γ . Our data provides the
321 framework for a potential mechanism of dysregulated immune cell infiltration and activation
322 in the CSF that is driven by metabolic changes during TBM treatment.

323 The immunometabolic shifts seen in the CSF of TBM patients showed only minor signs
324 of resolution after two months of effective treatment. In cluster 1 metabolites, which included
325 tryptophan and itaconate, there was no increase over the first 2 months of treatment and
326 these metabolites remained significantly lower than controls. While there was a significant

TB meningitis immunometabolic networks

327 decrease in metabolite cluster 3 with treatment, which included carnitines, kynurenines, and
328 lactate, these still remained significantly elevated relative to controls. Similarly, while
329 proinflammatory cytokines and chemokines (cluster 1) decrease with effective TBM
330 treatment, these cytokines remained significantly elevated relative to controls after two
331 months of treatment. This prolonged state of abnormal immunometabolic signaling follows
332 with clinical observations that mortality in TBM patients remains elevated months to years
333 after treatment initiation.(47) It also mimics what is seen for many chronic inflammatory
334 conditions where normal immune homeostasis is permanently altered even after removal of
335 the underlying cause of the disease.(48-50) This strongly supports consideration of TBM as
336 a chronic inflammatory condition which may require longer-term immunomodulatory
337 treatment.

338 This study is subject to several limitations. Cross-sectional comparison of CSF
339 metabolite and cytokine concentrations in TBM patients were made to a control group of
340 asymptomatic individuals. This makes it more difficult to distinguish which molecular
341 signatures are specific to TBM versus meningitis due to other causes. Additionally, the
342 relatively small sample size of TBM cases from a single geographic region may limit the
343 generalizability of the study. Though we demonstrate a strong association between CSF
344 concentrations of multiple metabolites and cytokines/chemokines, the observational nature of
345 the study precludes us from establishing a causal relationship. In future studies it will be
346 important to combine systemic measurement of soluble immune modulators in the CSF with
347 transcriptional profiling of immune cells in the CNS to better understand the immune cell
348 phenotypes and signaling pathways associated with pathologic metabolic signaling in TBM.
349 Additionally, mechanistic validation of the link between key metabolites and inflammatory
350 mediators can be assessed using *ex vivo* or *in vitro* stimulation systems.

TB meningitis immunometabolic networks

351 Overall, the data presented clearly demonstrate that soluble factors (cytokines and
352 metabolites) are critical features of the host immune environment which distinguish the
353 presence and severity of TBM. Our results provide insight into the metabolic drivers of CSF
354 inflammation in TBM, which are an integral part of inflammatory signaling networks. Given
355 the role of immunopathology in mediating adverse host outcomes in TBM, this will be a critical
356 area for further research. As these findings are expanded, it can be envisioned that signatures
357 of these host molecules could have utility as biomarkers of TBM, disease severity, and
358 response to TB treatment.

359

360

361 Acknowledgments

362 The authors thank the physicians, nurses, and staff at the NCTLD in Tbilisi, Georgia, who
363 provided care for the patients with TBM included in this study. Additionally, the authors are
364 thankful for study participants with tuberculosis meningitis who were willing to participate in
365 the study and help contribute meaningful data that may help future patients with the same
366 illness.

367

368

369

370

371

372

TB meningitis immunometabolic networks

373 **Conflict of Interest**

374 The authors declare that the research was conducted in the absence of any commercial or
375 financial relationships that could be construed as a potential conflict of interest.

376 **Author Contributions**

377 All authors agree to be accountable for the content of the work. JT and JC led the data
378 analysis, integration, and interpretation, as well as manuscript writing. JT and AS led the
379 cytokine analysis and JC led the metabolomics analysis. TB and SS provided the care for all
380 patients with TBM at the National Center for Tuberculosis and Lung Diseases and helped in
381 data collection and reviewed the manuscript drafts. AGCS assisted with data collection and
382 preparation and reviewed the manuscript drafts. MK and RRK led and designed the parent
383 clinical study, led project implementation, and assisted with data interpretation and reviewing
384 the manuscript.

385

386 **Funding**

387 This work was supported by grants from the National Institutes of Health (NIH) and National
388 Institute of Allergy and Infectious Diseases [R03AI139871, K23AI103044, K23AI144040,
389 P30AI168386, P30AI050409]; NIH Fogarty International Center [D43TW007124]; and NIH
390 National Center for Advancing Translational Science [UL1TR002378], Bethesda, MD, USA.

391

392

393

394

395

TB meningitis immunometabolic networks

396 **References**

- 397 1. Kalita J, Misra UK, Ranjan P. Predictors of long-term neurological sequelae of
398 tuberculous meningitis: a multivariate analysis. *Eur J Neurol.* 2007;14(1):33-7.
- 399 2. Kempker RR, Smith AGC, Avaliani T, Gujabidze M, Bakuradze T, Sabanadze S, et al.
400 Cycloserine and Linezolid for Tuberculosis Meningitis: Pharmacokinetic Evidence of
401 Potential Usefulness. *Clin Infect Dis.* 2022;75(4):682-689.
- 402 3. Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, et al.
403 Tuberculous meningitis. *Nat Rev Neurol.* 2017;13(10):581-98.
- 404 4. Burn CG, Finley KH. The role of hypersensitivity in the production of experimental
405 meningitis: I. Experimental meningitis in tuberculosis animals. *J Exp Med.*
406 1932;56(2):203-21.
- 407 5. Quinn CM, Poplin V, Kasibante J, Yuquimpo K, Gakuru J, Cresswell FV, et al.
408 Tuberculosis IRIS: Pathogenesis, Presentation, and Management across the Spectrum
409 of Disease. *Life (Basel).* 2020;10(11).
- 410 6. Pepper DJ, Marais S, Maartens G, Rebe K, Morrioni C, Rangaka MX, et al. Neurologic
411 manifestations of paradoxical tuberculosis-associated immune reconstitution
412 inflammatory syndrome: a case series. *Clin Infect Dis.* 2009;48(11):e96-107.
- 413 7. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, et al.
414 Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.
415 *N Engl J Med.* 2004;351(17):1741-51.
- 416 8. Whitworth LJ, Troll R, Pagán AJ, Roca FJ, Edelstein PH, Troll M, et al. Elevated
417 cerebrospinal fluid cytokine levels in tuberculous meningitis predict survival in response
418 to dexamethasone. *Proc Natl Acad Sci U S A.* 2021;118(10).
- 419 9. Saghazadeh A, Rezaei N. Central Inflammatory Cytokines in Tuberculous Meningitis: A
420 Systematic Review and Meta-analysis. *J Interferon Cytokine Res.* 2022;42(3):95-107.

TB meningitis immunometabolic networks

- 421 10. Koeken V, Ganiem AR, Dian S, Ruslami R, Chaidir L, Netea MG, et al. Cerebrospinal
422 fluid IL-1 β is elevated in tuberculous meningitis patients but not associated with
423 mortality. *Tuberculosis*. 2021;126:102019.
- 424 11. Sharma S, Goyal MK, Sharma K, Modi M, Sharma M, Khandelwal N, et al. Cytokines
425 do play a role in pathogenesis of tuberculous meningitis: A prospective study from a
426 tertiary care center in India. *J Neurol Sci*. 2017;379:131-6.
- 427 12. Thuong NTT, Heemskerk D, Tram TTB, Thao LTP, Ramakrishnan L, Ha VTN, et al.
428 Leukotriene A4 Hydrolase Genotype and HIV Infection Influence Intracerebral
429 Inflammation and Survival From Tuberculous Meningitis. *J Infect Dis*. 2017;215(7):1020-
430 8.
- 431 13. van Laarhoven A, Dian S, Aguirre-Gamboa R, Avila-Pacheco J, Ricano-Ponce I,
432 Ruesen C, et al. Cerebral tryptophan metabolism and outcome of tuberculous
433 meningitis: an observational cohort study. *Lancet Infect Dis*. 2018;18(5):526-35.
- 434 14. Ardiansyah E, Avila-Pacheco J, Nhat LTH, Dian S, Vinh DN, Hai HT, et al. Tryptophan
435 metabolism determines outcome in tuberculous meningitis: a targeted metabolomic
436 analysis. *Elife*. 2023;12.
- 437 15. Jain SK, Tobin DM, Tucker EW, Venketaraman V, Ordonez AA, Jayashankar L, et al.
438 Tuberculous meningitis: a roadmap for advancing basic and translational research. *Nat*
439 *Immunol*. 2018;19(6):521-5.
- 440 16. Smith AGC, Gujabidze M, Avaliani T, Blumberg HM, Collins JM, Sabanadze S, et al.
441 Clinical outcomes among patients with tuberculous meningitis receiving intensified
442 treatment regimens. *Int J Tuberc Lung Dis*. 2021;25(8):632-9.
- 443 17. Goetz ME, Hanfelt JJ, John SE, Bergquist SH, Loring DW, Quyyumi A, et al. Rationale
444 and Design of the Emory Healthy Aging and Emory Healthy Brain Studies.
445 *Neuroepidemiology*. 2019;53(3-4):187-200.

TB meningitis immunometabolic networks

- 446 18. Soltow QA, Strobel FH, Mansfield KG, Wachtman L, Park Y, Jones DP. High-
447 performance metabolic profiling with dual chromatography-Fourier-transform mass
448 spectrometry (DC-FTMS) for study of the exposome. *Metabolomics*. 2013;9(1
449 Suppl):S132-43.
- 450 19. Go YM, Walker DI, Liang Y, Uppal K, Soltow QA, Tran V, et al. Reference
451 Standardization for Mass Spectrometry and High-Resolution Metabolomics Applications
452 to Exposome Research. *Toxicological sciences*. 2015;148(2):531-42.
- 453 20. Yu T, Park Y, Johnson JM, Jones DP. apLCMS--adaptive processing of high-resolution
454 LC/MS data. *Bioinformatics*. 2009;25(15):1930-6.
- 455 21. Uppal K, Soltow QA, Strobel FH, Pittard WS, Gernert KM, Yu T, et al. xMSanalyzer:
456 automated pipeline for improved feature detection and downstream analysis of large-
457 scale, non-targeted metabolomics data. *BMC bioinformatics*. 2013;14:15.
- 458 22. Liu KH, Nellis M, Uppal K, Ma C, Tran V, Liang Y, et al. Reference Standardization for
459 Quantification and Harmonization of Large-Scale Metabolomics. *Anal Chem*.
460 2020;92(13):8836-44.
- 461 23. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
462 expression analyses for RNA-sequencing and microarray studies. *Nucleic Acid Res*.
463 2015;43(7):e47.
- 464 24. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing.
465 *Stat Med*. 1990;9(7):811-8.
- 466 25. Li S, Park Y, Duraisingham S, Strobel FH, Khan N, Soltow QA, et al. Predicting network
467 activity from high throughput metabolomics. *PLoS Comput Biol*. 2013;9(7):e1003123.
- 468 26. Collins JM, Siddiqa A, Jones DP, Liu K, Kempker RR, Nizam A, et al. Tryptophan
469 catabolism reflects disease activity in human tuberculosis. *JCI Insight*. 2020;5(10).

TB meningitis immunometabolic networks

- 470 27. Uppal K, Ma C, Go YM, Jones DP. xMWAS: a data-driven integration and differential
471 network analysis tool. *Bioinformatics*. 2017.
- 472 28. Collins JM, Jones DP, Sharma A, Khadka M, Liu KH, Kempker RR, et al. TCA cycle
473 remodeling drives proinflammatory signaling in humans with pulmonary tuberculosis.
474 *PLoS pathogens*. 2021;17(9):e1009941.
- 475 29. Gautam US, Foreman TW, Bucsan AN, Veatch AV, Alvarez X, Adekambi T, et al. In vivo
476 inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-
477 mediated control of *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A*.
478 2018;115(1):E62-e71.
- 479 30. Nair S, Huynh JP, Lampropoulou V, Loginicheva E, Esaulova E, Gounder AP, et al. Irg1
480 expression in myeloid cells prevents immunopathology during *M. tuberculosis* infection.
481 *J Exp Med*. 2018;215(4):1035-45.
- 482 31. Reinhardt RL, Kang SJ, Liang HE, Locksley RM. T helper cell effector fates--who, how
483 and where? *Curr Opin Immunol*. 2006;18(3):271-7.
- 484 32. Kim HR, Hwang KA, Park SH, Kang I. IL-7 and IL-15: biology and roles in T-Cell
485 immunity in health and disease. *Crit Rev Immunol*. 2008;28(4):325-39.
- 486 33. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-
487 Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. *N Engl J*
488 *Med*. 2021;384(18):1705-18.
- 489 34. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al.
490 Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis. *The*
491 *New England journal of medicine*. 2022;387(9):810-23.
- 492 35. Turkova A, Wills GH, Wobudeya E, Chabala C, Palmer M, Kinikar A, et al. Shorter
493 Treatment for Nonsevere Tuberculosis in African and Indian Children. *N Engl J Med*.
494 2022;386(10):911-22.

TB meningitis immunometabolic networks

- 495 36. Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, et al. Prednisone
496 for the Prevention of Paradoxical Tuberculosis-Associated IRIS. *N Engl J Med.*
497 2018;379(20):1915-25.
- 498 37. Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE, Loginicheva
499 E, et al. Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage
500 Metabolic Remodeling and Regulation of Inflammation. *Cell Metab.* 2016;24(1):158-66.
- 501 38. Mills EL, Ryan DG, Prag HA, Dikovskaya D, Menon D, Zaslona Z, et al. Itaconate is an
502 anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. *Nature.*
503 2018;556(7699):113-7.
- 504 39. Hooftman A, Angiari S, Hester S, Corcoran SE, Runtsch MC, Ling C, et al. The
505 Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome
506 Activation. *Cell Metab.* 2020;32(3):468-78.e7.
- 507 40. Darvish Khadem M, Tabandeh MR, Haschemi A, Kheirollah A, Shahriari A. Dimethyl
508 itaconate reprograms neurotoxic to neuroprotective primary astrocytes through the
509 regulation of NLRP3 inflammasome and NRF2/HO-1 pathways. *Mol Cell Neurosci.*
510 2022;122:103758.
- 511 41. Hoyle C, Green JP, Allan SM, Brough D, Lemarchand E. Itaconate and fumarate
512 derivatives inhibit priming and activation of the canonical NLRP3 inflammasome in
513 macrophages. *Immunology.* 2022;165(4):460-80.
- 514 42. Sheppard O, Coleman MP, Durrant CS. Lipopolysaccharide-induced neuroinflammation
515 induces presynaptic disruption through a direct action on brain tissue involving
516 microglia-derived interleukin 1 beta. *J Neuroinflammation.* 2019;16(1):106.
- 517 43. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, et al. Control of T(reg)
518 and T(H)17 cell differentiation by the aryl hydrocarbon receptor. *Nature.*
519 2008;453(7191):65-71.

TB meningitis immunometabolic networks

- 520 44. Desvignes L, Ernst JD. Interferon-gamma-responsive nonhematopoietic cells regulate
521 the immune response to *Mycobacterium tuberculosis*. *Immunity*. 2009;31(6):974-85.
- 522 45. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, et al. Tryptophan catabolism by
523 indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV
524 disease. *Science Transl Med*. 2010;2(32):32ra6.
- 525 46. Sühs KW, Novoselova N, Kuhn M, Seegers L, Kaefer V, Müller-Vahl K, et al.
526 Kynurenine Is a Cerebrospinal Fluid Biomarker for Bacterial and Viral Central Nervous
527 System Infections. *J Infect Dis*. 2019;220(1):127-38.
- 528 47. Evans EE, Avaliani T, Gujabidze M, Bakuradze T, Kipiani M, Sabanadze S, et al. Long
529 term outcomes of patients with tuberculous meningitis: The impact of drug resistance.
530 *PloS One*. 2022;17(6):e0270201.
- 531 48. Nganou-Makamdop K, Talla A, Sharma AA, Darko S, Ransier A, Laboune F, et al.
532 Translocated microbiome composition determines immunological outcome in treated
533 HIV infection. *Cell*. 2021;184(15):3899-914.e16.
- 534 49. Talla A, Vasaikar SV, Szeto GL, Lemos MP, Czartoski JL, MacMillan H, et al. Persistent
535 serum protein signatures define an inflammatory subcategory of long COVID. *Nat*
536 *Commun*. 2023;14(1):3417.
- 537 50. Meizlish ML, Franklin RA, Zhou X, Medzhitov R. Tissue Homeostasis and Inflammation.
538 *Annu Rev Immunol*. 2021;39:557-81.

539

540

541

542

543

544

TB meningitis immunometabolic networks

545 **Tables and Figure Legends (Figure files submitted separately)**

546

547 **Table 1**

	TB meningitis (n=17)	Controls (n=20)
Age, median (IQR)	36 (31-44)	59 (57-65)
Female sex, n (%)	9 (53)	10 (50)
Microbiologically confirmed TB meningitis, n (%)	5 (29)	NA
CSF total WBC, median (IQR)	209 (130-286)	NA
% Lymphocytes, median (IQR)	94 (85-96)	
% Neutrophils, median (IQR)	5 (2-8)	
TB meningitis grade, n (%)		NA
Grade 1	8 (47)	
Grade 2	9 (53)	

548

549

550

551

552

553

554

555

TB meningitis immunometabolic networks

556 **Figure 1** – (A) Volcano plot showing m/z features that were differentially abundant in the
557 cerebrospinal fluid of TBM cases versus controls. Those significantly increased in the CSF of
558 TBM cases (\log_2 fold change ≥ 0.5 and FDR-corrected p-value < 0.1) are in red while those
559 increased in the CSF of control participants are in blue. (B) Metabolic pathway analysis
560 showing metabolic pathways significantly enriched ($p < 0.05$) in TBM CSF (red) and those
561 significantly enriched in control CSF (blue). (C) Volcano plot of targeted metabolites
562 significantly increased in the CSF of TBM cases (red; \log_2 fold change ≥ 0.5 and FDR-
563 corrected p-value < 0.1) and those increased in the CSF of control participants (blue).
564 *Itaconate is isobaric with citraconate and mesoconate. (D) 2-way hierarchical clustering
565 analysis of targeted metabolites that significantly differed in TBM CSF versus control CSF.
566 Each column is annotated by whether the participant was diagnosed with TBM (red) versus
567 controls (blue), whether TBM was microbiologically confirmed (dark blue) or not (yellow), and
568 whether a TBM case had Grade 1 (grey) versus Grade 2 (green) severity.

569

570 **Figure 2** – (A) Principal component analysis of all 33 cytokines measured in the CSF showing
571 clear separation between control CSF (blue) and those with microbiologically confirmed TBM
572 (red) while those with unconfirmed TBM (purple) had some overlap with both groups. Principal
573 component 1 (x-axis) captured 59% of the variation in the data while principal component 2
574 (y-axis) captured 8%. (B) 2-way hierarchical clustering analysis of all measured cytokines
575 annotated by whether the participant was diagnosed with TBM (red) versus controls (blue),
576 whether TBM was microbiologically confirmed (dark blue) or not (yellow), and whether a TBM
577 case had Grade 1 (grey) versus Grade 2 (green) severity.

578

TB meningitis immunometabolic networks

579 **Figure 3** – (A) Pearson correlation heatmap of cytokines (x-axis) and differentially abundant
580 metabolites (y-axis) in controls (n=20) and TBM cases at baseline (n=14) with 2-way
581 hierarchical clustering. (B) Comparison of the centroid score of cluster 1 cytokines and (C)
582 cluster 3 metabolites in TBM cases at baseline versus controls. Groups were compared using
583 a Wilcoxon rank sum test (* $P \leq 0.05$, ** $P < 0.01$, *** $P < 0.001$). (D) Unbiased network analysis
584 showing all significant relationships between clinical characteristics of persons diagnosed
585 with TBM and cytokine and metabolite concentrations in CSF at the time of diagnosis. Positive
586 associations are denoted with red edges while negative associations are denoted with blue
587 edges. The intensity and width of the line corresponds to the strength of the association.

588

589 **Figure 4** – (A) Boxplots showing changes in cluster 1 cytokines after 7, 14, 28, and 56 days
590 of treatment in persons with TBM who clinically responded to therapy. (B) after 7 and 14 days,
591 treatment non-responders had elevated concentrations of cluster 1 cytokines versus
592 responders. (C) Cluster 3 metabolites also significantly declined in the CSF in treatment
593 responders. Cross sectional measures were compared with a Wilcoxon rank sum test while
594 repeat measures used a Wilcoxon signed rank test: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. (D)
595 Unbiased network analysis showing all significant relationships between clinical
596 characteristics of persons diagnosed with TBM and cytokine and metabolite concentrations
597 in CSF during treatment. Positive associations are denoted with red edges while negative
598 associations are denoted with blue edges. The intensity and width of the line corresponds to
599 the strength of the association.

600

601

TB meningitis immunometabolic networks

602 **Supplemental Figure 1** – (A) Cluster 1 metabolites including (B) tryptophan were
603 significantly decreased in the CSF of persons diagnosed with TBM versus asymptomatic
604 controls. (C) Cluster 2 metabolites were significantly increased in TBM versus asymptomatic
605 controls. Groups were compared using a Wilcoxon rank sum test (* $P \leq 0.05$, ** $P < 0.01$, *** P
606 < 0.001).

607

608 **Supplemental Figure 2** – (A) Cluster 2 cytokines (IL-7 and IL-9) were significantly lower in
609 the CSF of TBM patients versus asymptomatic controls while (B) Cluster 3 cytokines did not
610 differ between groups. (C) Cluster 3 cytokines were significantly increased in those with
611 Grade 2 TBM versus those with Grade 1 TBM. Groups were compared using a Wilcoxon rank
612 sum test (* $P \leq 0.05$, ** $P < 0.01$, *** $P < 0.001$).

613

614 **Supplemental Figure 3** – (A) Cluster 2 cytokines did not increase in the CSF in treatment
615 responders after 7, 14, 28, and 56 days of treatment and remained significantly lower than
616 asymptomatic controls. (B) Cluster 3 cytokines did not change with TBM treatment and
617 remained similar to concentrations in the CSF of asymptomatic controls. Cross sectional
618 measures were compared with a Wilcoxon rank sum test while repeat measures used a
619 Wilcoxon signed rank test: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

620


621

622


TB meningitis immunometabolic networks

623 **Supplemental Figure 4** – (A) Cluster 1 metabolites did not increase in the CSF in treatment
624 responders after 7, 14, 28, and 56 days of treatment and remained significantly lower than
625 asymptomatic controls. (B) Cluster 1 metabolites were lower in treatment non-responders
626 after 7 days of treatment versus treatment responders. (C) Cluster 2 metabolites significantly
627 decreased over the course of TBM treatment but remained significantly increased versus
628 asymptomatic controls. Cross sectional measures were compared with a Wilcoxon rank sum
629 test while repeat measures used a Wilcoxon signed rank test: * $p < 0.05$, ** $p < 0.01$, ***
630 $p < 0.001$.


A



B



C



D

